Walmart debuts first private brand analog insulin

The ReliOn NovoLog product could save customers hundreds of dollars on vials and FlexPens, per the retailer.
Dan Ochwat
Executive Editor
Dan Ochwat profile picture

Walmart has introduced the first private brand analog insulin product, a first in diabetes care, according to the retailer, and at a significant cost savings.

The product is under Walmart’s ReliOn private label brand and is called ReliOn NovoLog, providing customers with analog insulin vials at $72.88 and FlexPens at $85.88, a savings between 58% to 75% off the cash price of branded analog insulin products or a savings of up to $101 per branded vial or $251 per package of branded FlexPens, Walmart said. The prices are based on out-of-pocket costs that patients pay for insulin without a prescription drug insurance.


ReliOn NovoLog Insulin (insulin aspart) injection, manufactured by Novo Nordisk, will be available in Walmart pharmacies this week and Sam’s Club pharmacies in mid-July across the United States.

ReliOn NovoLog is a rapid-acting insulin analog used to control high blood sugar in adults and children with diabetes. Customers will need a prescription in order to purchase the products and should always consult with their doctor regarding their diabetes management, per Walmart.  

“We know many people with diabetes struggle to manage the financial burden of this condition, and we are focused on helping by providing affordable solutions. We also know this is a condition that disproportionately impacts underserved populations. With ReliOn NovoLog insulin, we’re adding a high-quality medication for diabetes to the already affordable ReliOn line of products and continuing our commitment to improve access and lowering cost of care,” said Cheryl Pegus, EVP, Walmart health and wellness.  

Walmart’s affordable ReliOn diabetes resources also include blood glucose monitors, lancets and other products to help manage the condition.

“Diabetes often comes with high medical costs, estimated around $9,601 per person per year,” said Tracey D. Brown, CEO of the Arlington, Va.-based American Diabetes Association. "We welcome all affordable solutions that make diabetes management more accessible to millions of Americans living with diabetes. We encourage everyone to ask their health care provider questions to better understand what the right and affordable treatment is for their unique medical needs.”